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ABSTRACT  30 
The antifungal effects of the novel triazole, PC1244, designed for topical or inhaled 31 
administration, against A. fumigatus have been tested in a range of in vitro and in vivo studies. 32 
PC1244 demonstrated potent antifungal activities against clinical A. fumigatus isolates (N=96) 33 
with a MIC range of 0.016–0.25 μg/ml, whereas the MIC range for voriconazole was 0.25–0.5 34 
μg/ml. PC1244 was a strong tight-binding inhibitor of recombinant A. fumigatus CYP51A and 35 
CYP51B (sterol 14α-demethylase) enzymes and strongly inhibited ergosterol synthesis in A. 36 
fumigatus with an IC50 of 8 nM. PC1244 was effective against a broad spectrum of pathogenic 37 
fungi (MIC ranged from <0.0078~2 μg/ml), especially on Aspergillus terreus, Trichophyton 38 
rubrum, Candida albicans, Candida glabrata, Candida krusei, Cryptococcus gattii, 39 
Cryptococcus neoformans and Rhizopus oryzae. PC1244 also proved to be quickly absorbed into 40 
both A. fumigatus hyphae and bronchial epithelial cells, producing persistent antifungal effects. 41 
In addition, PC1244 showed fungicidal activity (MFC, 2 μg/ml), which was 8-fold more potent 42 
than voriconazole. In vivo, once daily intranasal administration of PC1244 (3.2 ~ 80µg/mL) to 43 
temporarily neutropenic, immunocompromised mice 24h after inoculation with itraconazole-44 
susceptible A. fumigatus substantially reduced fungal load in the lung, galactomannan in serum 45 
and circulating inflammatory cytokines. Furthermore, 7 days extended prophylaxis with PC1244 46 
showed superior in vivo effects when compared against 1 day of prophylactic treatment, 47 
suggesting accumulation of the effects of PC1244. Thus, PC1244 has the potential to be a novel 48 
therapy for the treatment of A. fumigatus infection in the lungs of humans. 49 
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INTRODUCTION 51 
The incidence of fungal infections has increased substantially over the past two decades and 52 
invasive forms are leading causes of morbidity and mortality, especially amongst 53 
immunocompromised or immunosuppressed patients. In addition, chronic lung infections with 54 
Aspergillus, such as a previous infection with tuberculosis (1) or pulmonary inflammatory 55 
diseases, can leave patients with poor lung function, and extensive and permanent lung structual 56 
change (2-4).  57 
Systemic triazole therapy is the basis for treating infections with pathogenic fungi but the 58 
adverse effects of itraconazole (ITC), voriconazole (VRC) and posaconazole (POS) are well 59 
characterised and thought to be a consequence of the pharmacological effects of the compounds 60 
in host tissues (5-9). It has been observed that up to 15% of patients treated with voriconazole 61 
experience raised transaminase levels in the liver, a site of triazole toxicity (10, 11). Serious 62 
unwanted effects in other organs have been reported after oral or systemic VRC and POS 63 
treatment, and exposure of the liver also results in significant drug interactions arising from 64 
triazole inhibition of hepatic P450 enzymes (12, 13), although recent azoles isavuconazole and 65 
VT1161 showed better risk-benefit profiles in clinical or preclinical tests (14, 15).  66 
Administration of triazoles orally can lead to wide variations in patient response due to 67 
variable plasma concentrations, leading to compromised individual efficacy (16). Furthermore 68 
notable drug interactions for voriconazole due to the inhibition of hepatic P450 enzymes make 69 
clinical use challenging and indeed the variability in exposure of the triazoles via the oral route 70 
necessitates the need for close therapeutic drug monitoring and limits the use of triazole therapy 71 
prophylactically in at risk groups (13, 16). In addition, structural changes in the lung architecture, 72 
caused by chronic pulmonary disease or infection with tuberculosis, can lead to Aspergillus 73 
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colonisation of pre-existing cavities, limiting the efficacy of orally administered compounds 74 
which often struggle to penetrate into the pulmonary epithelial lining fluid (17). It is 75 
acknowledged that targeted administration to the lung, the primary point of infection, would 76 
prolong lung tissue residence and reduce systemic exposure, to display a better risk-benefit ratio. 77 
Recently, existing antifungal medications such as AMB, VRC and ITC have been repurposed in 78 
this manner to effectively prevent invasive disease (18-20).  79 
In this report we disclose the in vitro and in vivo activities of a newly discovered azole 80 
class, antifungal agent: 4-(4-(4-(((3R,5R)-5-((1H-1,2,4-triazol-1-yl)methyl)-5-(2,4-81 
difluorophenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-N-((1S,2S)-2-82 
hydroxycyclohexyl)benzamide, (referred to here as PC1244, Fig 1) (21). The compound 83 
demonstrates activities comparable to POS and superior to VRC against both ITC susceptible 84 
and resistant strains, and it has been designed to have physicochemical properties suitable for 85 
topical administration to the lung and promote long lasting tissue residency.86 
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RESULTS 87 
In vitro antifungal activity against laboratory adopted strains of A. fumigatus. The 88 
antifungal activity of test compounds against A. fumigatus strains (Itraconazole (ITC) 89 
susceptible-NCPF2010, AF294, AF293; ITC-resistant-AF72, AF91) were calculated from 90 
growth curves generated by spectrophotometric analysis and compared to positive and negative 91 
controls. 92 
It was observed that significantly lower concentrations of PC1244 were needed for endpoints 93 
(50% inhibition (IC50 [OD]) and 90% inhibition (IC90 [OD]) than those of all reference 94 
compounds, including voriconazole (VRC), posaconazole (POS) and itraconazole (ITC), against 95 
ITC-susceptible A. fumigatus laboratory strains (NCPF2010, AF294, AF293, Table 1) (22, 23). 96 
In addition, PC1244 was the most active test agent against known ITC-resistant A. fumigatus 97 
strains (AF72, AF91) (24, 25) (Table 1).  98 
 99 
In vitro antifungal activity against clinically isolated A. fumigatus. The antifungal activity of 100 
PC1244 was further evaluated in 96 clinical isolates [obtained from the Saint Louis Hospital, 101 
Paris, France (50 isolates) and NW Mycology Centre, Manchester, UK (46 isolates)]. In this 102 
study, PC1244 was found to be 6.2-fold more potent than VRC and demonstrated comparable 103 
effects to POS based on their geometric means (Table 2, Fig 2). During this assay, the quality 104 
control strain A. fumigatus ATCC204305 was used for validation and posaconazole showed a 105 
MIC of 0.25 µg/ml, within the range set by the EUCAST guidelines. 106 
 107 
In vitro assessment of antifungal activity using CLSI methodology. A. fumigatus growth 108 
inhibition by PC1244 was confirmed by the CLSI method as well as the EUCAST microdilution 109 
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method. Following the CLSI methodology guidelines (M38-A (26)), the growth of four ITC-110 
susceptible laboratory A. fumigatus strains was assessed visually. PC1244 generated a MIC 111 
(0.063 μg/ml) which was comparable to POS (0.047 μg/ml) and 8-fold more potent than VRC 112 
(0.5 μg/ml).  113 
 114 
CYP51 binding properties. Both PC1244 and POS produced type II difference spectra when 115 
titrated against purified recombinant A. fumigatus (AF293) CYP51A and CYP51B enzymes. 116 
PC1244 bound with similar affinities to the two isoenzymes as POS (CYP51A, Kd values 0.74 117 
and 0.96 μM for PC1244 and POS, respectively; CYP51B, Kd values of 0.018 and 0.012 μM, 118 
respectively) (Fig 3A, B). The low-end accuracy limit for Kd determinations using the modified 119 
Morrison equation is ~0.5 to 1% of the enzyme concentration (27), i.e. 0.020 to 0.040 μM in this 120 
study. Consequently, calculated Kd values below 0.020 μM should be treated numerically as 121 
<0.020 μM. 122 
 123 
Inhibitory activity against A. fumigatus CYP51 enzyme. The inhibitory activities of PC1244 124 
against A. fumigatus sterol 14α-demethylases were determined using 0.5 μM A. fumigatus 125 
CYP51A and 0.5 μM CYP51B in the membrane fraction prepared from Escherichia coli 126 
expression clones, and compared to those of posaconazole. Both PC1244 and POS were strong 127 
tight-binding inhibitors of CYP51A and CYP51B in vitro activity (CYP51A IC50 values for 128 
PC1244 and POS: 0.27 and 0.16 μM; and CYP51B IC50 values of 0.23 and 0.17 μM, 129 
respectively), suggesting Ki.app values below 1 nM (27), with PC1244 being equally as effective 130 
as POS (Fig 3C, D). This data suggests that both agents share the same mode of action; by 131 
directly coordinating as the sixth axial ligand of the CYP51 heme iron. 132 
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 133 
Cell based A. fumigatus sterol composition and CYP51 assay. The sterol composition of A. 134 
fumigatus (NCPF2010) was determined for cells treated with 0, 0.0001, 0.001, 0.01, 0.1, and 1 135 
µg/ml PC1244 and posaconazole. Sterols were extracted by saponification with KOH followed 136 
by extraction with n-hexane and TMS-derivatisation prior to analysis by GC/MS. Azole 137 
treatment of A. fumigatus resulted in the dose dependent accumulation of the 14 α-methylated 138 
sterols (lanosterol and eburicol) and the corresponding depletion of the final sterol product: 139 
ergosterol (Table 3), characteristic of cellular CYP51 inhibition.   140 
CYP51 enzyme inhibitory activity was also measured in a cell-based assay, as described 141 
previously (28). In this plate-based ergosterol quantification experiment, oxidation of ergosterol 142 
by cholesterol oxidase was determined by observing the conversion of the weakly fluorescent 143 
resazurin to the highly fluorescent resorufin, and was normalised using crystal violet staining 144 
(indicating cell number). Mirroring the inhibitory activity observed in the cell-free model of 145 
CYP51 and the sterol profiles of treated cells, PC1244 strongly inhibited ergosterol production 146 
(IC50 = 0.0055 μg/ml; 0.0080 μM) and was 12-fold more potent than VRC (IC50 = 0.067 μg/ml; 147 
0.19 μM) and 2.2-fold more potent than POS (IC50 = 0.012 μg/ml; 0.017 μM). 148 
 149 
In vitro determination of persistence of action. The duration of action of test agents within the 150 
hyphae of A. fumigatus has been determined using a resazurin-based microtiter assay (28). A. 151 
fumigatus hyphae were exposed to test agents for 16 h and the inhibition of fungal growth was 152 
measured, and the efficacy was compared with that obtained after contact with drug for only 20 153 
minutes, followed by washout and incubation for the same period. As seen in Table 4, it was 154 
observed that PC1244 (IC50: 0.00011 μg/ml) was 100 and 4.1-fold more potent than VRC and 155 
POS, respectively, at inhibiting hyphal A. fumigatus growth. In addition, the potency of VRC and 156 
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POS diminished markedly, after short contact and washout, by factors of >93-fold and 4.9-fold, 157 
respectively. In contrast, washout produced only a 2.4-fold reduction in the activity of PC1244 158 
compared with continuous contact in this experimental paradigm (Table 4, Fig 4A and B).  159 
In a second system, the persistence of action of the same three agents on A. fumigatus-160 
infected bronchial epithelial cells was quantified using GM production in the culture supernatant 161 
as an index of fungal growth. BEAS2B cells were infected with A. fumigatus, and the effects of a 162 
24 h washout period (media change) prior to infection were examined. A one hour contact time 163 
with PC1244 followed by 24 h washout resulted in a 5.4-fold loss of potency against A. 164 
fumigatus, compared with the control where there was no washout. POS showed a greater loss of 165 
its activity on washout (14.7-fold) and it was particularly notable that VRC was ineffective under 166 
the same test conditions (Table 4, Fig 4C and D). The pattern of effects mirror those seen in A. 167 
fumigatus hyphae (above) and imply that only a short contact period of bronchial epithelial cells 168 
with PC1244 would be required for the agent to exert a long duration of therapeutic action.  169 
  170 
In vitro fungicidal activity against A. fumigatus. The MFC for each compound was calculated 171 
48 h after supernatants from the MIC assay were transferred to agar plates, and determined to be 172 
the lowest concentration of compound that yielded 3 colonies or less (CFU-MFC). PC1244 173 
exhibited the greatest CFU-MFC of all compounds tested (2 µg/ml), and was 2 and 8-fold 174 
stronger than POS and VRC, respectively. The ratios of CFU-MFC versus MIC were 32, 32 and 175 
9.6 for PC1244, POS and VRC, respectively (Table 5). 176 
In addition, the fungicidal effect of each compound was determined using an XTT based 177 
quantitative colorimetric analysis (XTT-MFC). Absorbance was measured at OD450-620, 24 h after 178 
supernatant including compound was removed from the wells used for broth microdilution MIC 179 
assay. Again, PC1244 exhibited the greatest level of inhibition of all compounds tested with a 180 
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XTT-MFC of 0.14 µg/ml. In this system, PC1244 was 3-fold more potent than POS and >229-181 
fold more potent than VRC. The maximum inhibition of fungicidal activities for PC1244, POS 182 
and VRC were 99.9% at 1 µg/ml, 100% at 2 µg/ml and 69.2% at 32 µg/ml, respectively. In 183 
addition, the ratios of XTT-MFC versus MIC were 2.2, 3.4 and >19 for PC1244, POS and VRC, 184 
respectively (Table 5, Fig 5). 185 
 186 
In vivo antifungal activity on ITC susceptible A. fumigatus infection. To assess the in vivo 187 
activity of PC1244, temporarily neutropenic mice infected with A. fumigatus (ATCC13073 188 
[strain: NIH 5233]) were used. MIC values of PC1244, POS, VRC and ITC against this strain 189 
were 0.063, 0.125, 0.5 and 0.5 µg/ml, respectively.  An aqueous suspension of PC1244 in 190 
isotonic saline (0.0032, 0.016 and 0.08 mg/ml, 35µl, please see the table 6 for conversion to 191 
mg/mouse or approximately mg/kg) was dosed by intranasal injection once daily for 3 days post 192 
infection with ITC-susceptible A. fumigatus. This “late intervention” regimen was found to 193 
strongly inhibit fungal load (CFU) in the lung, the highest dose (0.08 mg/ml) administered 194 
exhibiting 97% inhibition, when compared to vehicle (Fig 6A). In comparison, POS, given at the 195 
same level of 0.08 mg/ml, achieved only 39% inhibition of lung fungal load and the IDLog10 value 196 
(the dose to reduce 1 log10 of CFU/g) was 2.0 mg/ml (70µg/mouse)) which was 143-fold higher 197 
than that of PC1244 (ID Log10 : 0.014 mg/ml (0.49µg/mouse)). PC1244 also decreased GM 198 
concentrations in BALF in a dose-dependent manner, showing ID50 value of 0.032 mg/ml (1.1 199 
µg/mouse), which was 6.7fold lower than that of POS (ID50: 0.21 mg/ml (7.4 µg/mouse)) (Fig 200 
6B). PC1244 decreased GM concentrations in serum in a dose-dependent manner, too (Fig 4C). 201 
Notably, 0.08 mg/ml (2.8 µg/mouse) of PC1244 produced marked inhibition (82% inhibition) of 202 
GM in serum, whereas POS, at the same dose, did not show any effect (-11% inhibition). In pilot 203 
study, we also measured A. fumigatus PCR products in lung tissue, and consistent with these data 204 
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above, PC1244 inhibited the accumulation of PCR product(Supplement Fig 1B). In addition, 205 
PC1244 also reduced A.fumigatus infection dependent increase in CXCL1 in BALF (Fig 6D), 206 
IL-6 (Fig 6E) and TNFα levels (Fig 6E4D) in serum.  207 
Extended prophylaxis with PC1244 [0.0032 mg/ml (0.11 µg/mouse); -7/0] achieved a 208 
high level of inhibitory effects on fungal load and biomarkers when compared to that observed in 209 
the late intervention study (Day 1-3 treatment) at the same dose (Fig 6A vs. 7A,  Fig 6C vs. Fig 210 
7B).  Furthermore, a marked difference between extended prophylaxis (-7/0) and a shorter period 211 
of treatment (-1/0) was also observed on CFU in lung, galactomannan in serum and MDA 212 
(malondialdehyde, an oxidative stress marker) in BALF (Fig 7A, B and C). 213 
As we indicated persistent action of PC1244 in the in vitro system eralier, the persistent 214 
action was also evaluated in vivo. As the MIC value on the A. fumigatus strain (ATCC13073) 215 
used in this study was 2-fold lower in PC1244 than POS, PC1244 at 0.4 mg/ml (14 µg/mouse) 216 
and POS at 0.8 mg/ml (28 µg/mouse) were intranasally administered 16 h before A. fumigatus 217 
inoculation, and the lungs were collected for GM and CFU assessment 8 h after A. fumigatus 218 
inoculation. As observed in Fig. 8A and B, PC1244 showed significant inhibition on both GM 219 
and CFU in the lung, but POS did not despite of administration at a 2-fold higher dose. Thus, in 220 
the in vivo system, persistent action of PC1244 was confirmed.  221 
 222 
Antifungal activity against non-A. fumigatus species. The in vitro activity of PC1244 was 223 
compared with VRC, and POS against 23 pathogenic fungi (1~2 isolates each) and the results are 224 
displayed in Table 7. In all non-Aspergillus and non-Candida species tested, PC1244 was more 225 
potent or comparable in potency to POS and VRC. Of particular note, PC1244 was effective 226 
(MIC, 0.25 – 2 μg/ml) against species in which VRC and POS had no effect within the 227 
concentration range tested (MIC, >8 μg/ml), including Gibberella zeae (Fusarium 228 
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graminearum), Lichtheimia corymbifera, Mucor circinelloides, Rhizomucor pusillus and 229 
Rhizopus oryzae. PC1244 was found to have antifungal activity against A. flavus, A. niger, and A. 230 
terreus, albeit with less potency than POS. Against Aspergillus carbonarius, PC1244 was 231 
equally potent to POS and more potent than VRC. Against all Candida species tested (Candida 232 
albicans, Candida glabrata, Candida krusei and Candida parapsilosis), PC1244 was more 233 
potent than VRC, and stronger or comparable in potency to POS in its inhibitory activity. 234 
 235 
DISCUSSION 236 
In this report, we present data demonstrating that: 1. the novel triazole PC1244 possesses both 237 
potent and persistent antifungal activity and significant fungicidal activity against ITC 238 
susceptible and/or ITC resistant A. fumigatus in vitro, 2. the antifungal activity was confirmed in 239 
clinical isolates from two geographical areas, 3. intranasal once-daily PC1244 treatment 240 
exhibited potent antifungal effects against A. fumigatus in vivo, in temporarily neutropenic mice, 241 
4. PC1244 showed a broad range of antifungal activity when screened against a panel of 242 
pathogenic fungal organisms. 243 
  The proposed mechanism of action of PC1244 is inhibition of sterol 14α-demethylase 244 
(CYP51A1), the enzyme required to convert eburicol to 14-demethylated eburicol, an essential 245 
step in the ergosterol biosynthesis pathway in fungi. Type II binding spectra, which display an 246 
Amax at 423-430 nm and a broad trough at 386-412 nm arise through a specific interaction in 247 
which the triazole N-4 nitrogen (posaconazole) or the imadazole ring N-3 nitrogen coordinates as 248 
the sixth axial ligand with the heme iron to form a low-spin CYP51-azole complex (29, 30). 249 
PC1244 produced type II difference spectra when titrated against purified recombinant ITC-250 
susceptible A. fumigatus (AF293) CYP51A and CYP51B, and bound with a similar affinity to 251 
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both enzymes as posaconazole. Furthermore, the strong inhibition of CYP51A activity observed 252 
with both PC1244 and posaconazole, characteristic of tight-binding inhibitors (IC50 value 253 
approximately half that of the enzyme concentration present), exceeded that predicted by the 254 
calculated Kd values from ligand binding studies using recombinant CYP51A, suggesting that the 255 
conformation of purified CYP51A in solution differs from that in cell membranes.  256 
In sterol composition determinations, treatment with increasing concentrations of either 257 
PC1244 or posaconazole, from 0 to 1 µg/ml, resulted in an accumulation of the 14-methylated 258 
sterols, lanosterol and eburicol, and depletion of the final sterol product, ergosterol; this pattern 259 
of effect is consistent with CYP51 inhibition being the key pharmacological activity of both 260 
agents. In addition, a cell-based assay of ergosterol biosynthesis in A. fumigatus demonstrated 261 
that PC1244 was 12 and 2.2-fold more potent at inhibiting ergosterol production than 262 
voriconazole and posaconazole, respectively. Thus, the mechanism of action of PC1244, as for 263 
other triazole antifungals, is the inhibition of fungal sterol 14α-demethylase, resulting in the 264 
depletion of ergosterol in the fungal membrane so disrupting membrane structure and function 265 
and inhibiting growth of the pathogenic organism (31).  266 
A highly desirable feature of topical medicines is a long duration of action ensuring that 267 
the desired therapeutic activity is maintained throughout the inter-dose period. This is 268 
particularly relevant to the treatment of pulmonary infection with A. fumigatus, which germinates 269 
in both extracellular environments and intracellular compartments. The duration of action of 270 
PC1244 was therefore considered an important property and was evaluated in a variety of in vitro 271 
systems. In A. fumigatus hyphae, the IC50 value measured for PC1244 following a 20 minute 272 
contact period and washout for 16 h was reduced only 2.4-fold relative to that obtained following 273 
continuous contact with the drug for the same period without washout. Furthermore, in the 274 
BEAS2B cell line, washout for 24 h, after a 1 h contact period, resulted in only an approximate 275 
 o
n
 M
arch 10, 2018 by University of W
ales Swansea
http://aac.asm
.org/
D
ow
nloaded from
 
AAC (Research Article, T.Colley/G.Sehra) 
14 
 
5-fold loss of potency against A. fumigatus compared with control. These observed properties of 276 
rapid cellular penetration and persistence of action, in the absence of the pathogen, may be 277 
particularly valuable characteristics, which enhance the potential use of PC1244 in prophylaxis. 278 
The persistent action of PC1244 was also confirmed in the in vivo system when administered 16 279 
h before A. fumigatus inoculation (Figure 5). 280 
In the in vivo system, intranasal treatment of PC1244 showed better effects than 281 
posaconazole despite comparable MIC values in in vitro testing. We speculate that, firstly, 282 
persistence of the drug substance on bronchial cells, as shown in Figure 4, is likely to be a 283 
contributory factor to the amplification of the antifungal effects of PC1244 in vivo seen in the 284 
current once daily treatment regimen. Secondly, we have demonstrated here that a 7 day 285 
extended prophylactic treatment (using very low doses) produced much greater anti-Aspergillus 286 
activity than prophylactic treatment for 1 day, and also that the effects of 7 day prophylactic 287 
treatment are maintained if treatment ceased when Aspergillus is inoculated on day 0 (Fig. 7). 288 
This is powerful pharmacodynamic evidence that the effects of PC1244 accumulate on daily 289 
dosing in mice and are maintained when dosing is terminated. Thirdly, Baistrocchi and 290 
colleagues published evidence of the accumulation of posaconazole in granulocyte type cells and 291 
demonstrated enhanced synergic antifungal effects (by exposure of Aspergillus to cellular 292 
posaconazole during phagocytosis) (32). Considering the persistent action of PC1244, it is likely 293 
that granulocytes/macrophages containing PC1244 contributed to further enhancement of the 294 
antifungal effect.  295 
Determining whether an antifungal compound is “fungistatic” or “fungicidal” is complex 296 
and the clinical utility of such characterisation is the subject of much debate. Fungal infections of 297 
body compartments that are not easily accessed by host defences require agents that are 298 
fungicidal in nature, and this is especially true in immunocompromised patients (33). For an 299 
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antibiotic to qualify as bactericidal its minimum bactericidal concentration (MBC) must be no 300 
more than 2× to 4× the MIC, but the definition of “fungicidal” is yet to be standardised (33). 301 
MFC determination in filamentous fungi is not standardised either, but studies have shown that 302 
reproducible MFCs can be obtained by following standardised broth microdilution methods for 303 
MIC determination, followed by subculture onto agar (33, 34). Defining an MFC as the lowest 304 
drug dilution to yield less than 3 colonies to obtain 99% - 99.5% killing activity, Espinel-Ingroff 305 
et al determined the MFC90 range of itraconazole (0.2 – 4 μg/ml), voriconazole (0.5 – 4 μg/ml) 306 
and posaconazole (0.06 – 2 μg/ml), in a number of A. fumigatus isolates (34). However, it is 307 
worth noting that the agar subculture methodology tests for fungicidal activity on planktonic Af 308 
growth only. Here we have used a combination of different methodologies to attempt to 309 
determine the fungicidal activity of PC1244 and clinically used triazoles accurately. Using 310 
subculture on agar (CFU-MFC) gave an MFC of 2 μg/ml for PC1244 with an MFC/MIC ratio of 311 
32, and similar results were seen with posaconazole (MFC = 4 μg/ml, MFC/MIC = 32), whilst 312 
voriconazole exhibited a higher MFC (16 μg/ml) but a lower MFC/MIC ratio (9.6). As discussed 313 
above, this data would suggest voriconazole is a more fungicidal compound as it exhibits a lower 314 
MFC/MIC ratio. However, recent studies have shown that this technique likely overestimates the 315 
fungicidal activity of a compound as it does not factor in viable conidia attached to the base of 316 
test wells (35). To account for this phenomenon, a colorimetric method for assessing the 317 
fungicidal activity of a compound against sessile A. fumigatus was used (35). MFC determination 318 
by this microbroth colorimetric method (XTT-MFC) gave an MFC of 0.14 μg/ml for PC1244 319 
with an MFC/MIC ratio of 2.2, which was superior to both posaconazole (MFC = 0.42 μg/ml, 320 
MFC/MIC = 3.4) and voriconazole (MFC = >32 μg/ml, MFC/MIC = >19). Therefore, with these 321 
data we provide evidence that PC1244 is a fungicidal compound with a similar or improved 322 
degree of potency to posaconazole.  323 
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 As with any study there are limitations, especially the in vivo study. Firstly, the delivery 324 
system does not mimic clinical use. The advantage of intranasal instillation is being able to 325 
confirm that all the solution is delivered into the body, but we do not control the level of lung 326 
exposure or the exposure site (same as aerosolization). However, we carefully optimised the 327 
intranasal dosing volume, as it has been shown that approximately 60% of the administered dose 328 
will be deposited in the lung after intranasal treatment (36) and also we confirmed trachea/lung 329 
deposition after intranasal administration of 35 µL of methylene blue solution to A/J mice (data 330 
not shown). Aerosolization with close drug monitoring at the exposure site (rather than systemic) 331 
is ideal, but this is not easily achieved as special imaging equipment is required, as Miller et al 332 
demonstrated elegantly using whole-Animal Luminescent Imaging (37). Secondly, CFUs were 333 
determined in only whole left lobe. This will cause location bias of fungal load, and ideally we 334 
should test in homogenate from the whole lung. However, when we determined CFU and GM in 335 
right lobe and left lobe, we did not find any significant difference of these biomarkers between 336 
right lobe and left lobe (data not shown). In addition, to avoid this bias, we determined GM in 337 
BALF and serum. Thirdly, there was a lack of pharmacokinetic measurement of PC1244 in mice 338 
used for the in vivo study. PC1244 has been optimised for topical treatment to the lung to 339 
maximize local exposure and minimise systemic exposure. Systemic concentrations of drug are 340 
therefore not a useful surrogate marker to help explain the different antifungal efficacy of 341 
compounds. However, we have some data demonstrating that measurable levels of systemic 342 
exposure do occur. In preliminary studies using non-infected mice dosed intra-tracheally with 40 343 
µL of a 2 mg/ml aqueous suspension of PC1244, it was shown that the plasma concentrations of 344 
PC1244 ranged from 111 ~ 303 ng/ml 2 hours post dose, and 249 ~ 339 ng/ml 8 hours post dose. 345 
But this had been reduced to 41.5 ~ 50.7 ng/ml 24 hours post dose despite decent in vivo effects 346 
after once daily treatment. Under the same conditions, the plasma concentrations achieved with 347 
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posaconazole were 15.6 ~ 125 ng/ml at 24 hours post dose, which was more variable but not too 348 
different from that of PC1244, although the in vivo activity of PC1244 was superior to that of 349 
posaconazole. As PC1244 has much less oral availability compared with posaconazole 350 
(unpublished data), the exposure results from absorption through the respiratory tract (not by 351 
accidental ingestion of compound during dosing). Furthermore, all compounds are water 352 
insoluble, and administered topically (exposed to respiratory tract directly). We do not, therefore, 353 
believe that water solubility is a key factor explaining the in vivo efficacies or topical exposure 354 
levels. Finally, we tested only limited isolates of azole resistant strains. Further study will be 355 
required with a wide range of clinical azole resistant isolates with different genotypes to 356 
determine its potency against recent A. fumigatus strains with TR34/L98H and 357 
TR46/Y121F/T289A mutations or other genetic cause(s) underlying resistance.  358 
 Thus, due to its superior or comparable activity against both azole susceptible and azole 359 
resistant A. fumigatus, persistent action, extended retention within the lung after topical treatment 360 
and broad repertoire of fungal targets, PC1244 has the potential to become a valuable new 361 
therapeutic agent for the treatment of A. fumigatus and other, difficult to treat, fungal infections 362 
in man.  363 
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MATERIALS & METHODS 364 
Antifungal agents. PC1244 was synthesised by Sygnature Discovery Ltd (Nottingham, UK), 365 
and voriconazole (Tokyo Chemical Industry UK Ltd., Oxford, UK), posaconazole (Apichem 366 
Chemical Technology Co., Ltd., Zhejiang, China), itraconazole (Arkopharma, Carros, France), 367 
amphotericin B (Selleckchem, Munich, Germany) and caspofungin (Selleckchem, Munich, 368 
Germany) were procured from commercial sources. For in vitro antifungal assays, stock 369 
solutions of test agents were prepared in DMSO (2000 μg/ml). For in vivo studies, solid materials 370 
of test agents were directly suspended in physiological saline at 10 mg/ml, and diluted with 371 
physiological saline after sonication.  372 
 373 
A. fumigatus CYP51 binding assay and enzyme inhibitory activity. A. fumigatus CYP51 374 
binding properties were determined as previously reported (28, 38). Test agents were titrated 375 
against 4 μM recombinant A. fumigatus (AF293 strain) CYP51A or CYP51B proteins and 376 
binding saturation curves were constructed from the change in the absorbance between the 377 
spectral peak and the trough. A rearrangement of the Morrison equation was used to determine 378 
the dissociation constant (Kd) values when ligand binding was tight (39).  379 
A CYP51 reconstitution assay system was used to determine 50% inhibitory (IC50) 380 
concentrations (40). Test agent was added to a mixture of 0.5 μM CYP51, 1 μM A. fumigatus 381 
cytochrome P450 reductase isoenzyme 1 (AfCPR1), 50 μM eburicol, 4% (w/v) 2-hydroxypropyl-382 
β-cyclodextrin, 0.4 mg/ml isocitrate dehydrogenase, 25 mM trisodium isocitrate, 50 mM NaCl, 5 383 
mM MgCl2 and 40 mM 3-(N-morpholino) propanesulfonic acid (MOPS; pH ~7.2). The mixtures 384 
were then incubated at 37°C for 10 minutes prior to initiation with 4 mM β-NADPHNa4 385 
followed by shaking for 20 minutes at 37°C. Sterol metabolites were recovered by extraction 386 
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with ethyl acetate followed by derivatisation with 0.1 ml N,O-387 
bis(trimethylsilyl)trifluoroacetamide : trimethylchlorosilane (99:1) and 0.3 ml anhydrous 388 
pyridine prior to analysis by gas chromatography mass spectrometry. 389 
 390 
A. fumigatus sterol analysis. A working suspension of A. fumigatus spores (NCPF2010) was 391 
prepared in filter-sterilised MOPS RPMI-1640 (RPMI-1640 containing 2 mM L-glutamine, 2% 392 
glucose, 0.165 M MOPS, buffered to pH 7 with NaOH) at a final concentration of 8 x 10
6
 spores 393 
ml
-1
. To each 100 mm Petri dish, 10 ml of the working suspension was added and the dishes 394 
were incubated for 4 h at 35°C and 5% CO2. Samples for baseline determinations were collected 395 
by scraping, pelleted by centrifugation at 2000 rpm for 5 minutes and stored at -80°C. Test 396 
compounds or DMSO (50 µl) were added to the remaining dishes, which were subsequently 397 
gently rocked by hand to disperse the compounds. Dishes were incubated for 2 h at 35°C and 5% 398 
CO2. Samples were collected and processed as described above. Posaconazole and PC1244 399 
concentrations of 0.0001, 0.001, 0.01, 0.1 and 1 µg ml
-1
 were tested. These samples were 400 
prepared in the laboratory at Pulmocide Ltd., and sent to the laboratory in the Centre for 401 
Cytochrome P450 Biodiversity, Institute of Life Science, Swansea University Medical School, 402 
for analysis. 403 
 Non-saponifiable lipids were extracted as previously reported (31) and were derivatised 404 
with 0.1 ml N,O-bis(trimethylsilyl)trifluoroacetamide : trimethylchlorosilane (99:1) and 0.3 ml 405 
anhydrous pyridine (2 h at 80°C) prior to analysis by gas chromatography mass spectrometry 406 
(41). Sterol composition was calculated using peak areas from the gas chromatograms and the 407 
mass fragmentation patterns compared to known standards were used to confirm sterol identity. 408 
The sterol content of A. fumigatus (basal) and treated A. fumigatus (either DMSO, posaconazole 409 
or PC1244) were determined in three biological replicates.  410 
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 411 
A. fumigatus cell based ergosterol assay. Growth medium (RPMI-1640, 2 mM L-glutamine, 412 
2% glucose, 0.165 M MOPS, 0.5% BSA, pH 7.0) was added across a 96-well plate and test 413 
agents were added in duplicate. A. fumigatus (NCPF2010) conidia were added across the plate at 414 
a final concentration of 1 x 10
4
 ml
-1
. After incubation for 24 h at 35°C, media was removed from 415 
all wells and replaced with reaction buffer (Amplex red cholesterol assay kit, ThermoFisher, 416 
A12216) and Amplex red solution. Plates were incubated for 30 minutes at 37°C, protected from 417 
light, after which fluorescence was quantified using a spectrophotometer. Media was removed 418 
from all wells and replaced with crystal violet solution (1% 
v
/v), and plates were incubated at 419 
room temperature on a shaker for 30 minutes. Plates were washed three times with PBS, and 420 
sodium dodecyl sulphate solution (0.1% 
v
/v) was added across the plate to lyse the cells. After 421 
incubation at room temperature for 1 h, absorbance was measured at OD590 using a 422 
spectrophotometer. 423 
 424 
In vitro antifungal activity against A. fumigatus. Assessment of antifungal activity against a 425 
selection of A. fumigatus laboratory/clinical strains (NCPF2010 [National Collection of 426 
Pathogenic Fungi (NCPF), Bristol, UK], AF72 [NCPF, Bristol, UK], AF91 [NCPF, Bristol, UK], 427 
AF293 [NCPF, Bristol, UK], AF294 [NCPF, Bristol, UK]) was performed using EUCAST 428 
methodology as previously reported (28), in a 384-well plate format as quadricates, in three 429 
independent experiments. Growth medium (RPMI-1640, 2 mM L-glutamine, 2% glucose, 0.165 430 
M MOPS, 0.5% BSA, pH 7.0) was added across the plate, test agents were added in 431 
quadruplicate and the DMSO concentration was identical across the plates. Conidia were added 432 
across the plate at a final concentration of 1 x 10
5
 ml
-1
. Plates were incubated for 48 h at 35°C 433 
after which turbidity was assessed by measuring optical density (OD) at 530 nm using a 434 
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spectrophotometer, and the IC50 and IC90 values were calculated from the concentration-response 435 
curve generated for each test compound using a four-parameter logistic equation (Dotmatics, 436 
Bishops Stortford, UK). A. fumigatus ATCC204305 was used as the assay control. 437 
Determination of antifungal activity against 50 A. fumigatus clinical isolates from St Louis 438 
Hospital (Paris, France) was performed with 96-well plates using the EUCAST method shown 439 
above (28) in duplicate. Antifungal susceptibility testing for 46 A. fumigatus isolates [obtained 440 
from the North West England Mycology Reference Centre] was performed as singlicate by 441 
Evotec (UK) Ltd (Manchester, UK) according to EUCAST guidelines. Assessment of the 442 
antifungal activity of four of the A. fumigatus strains (ATCC1028, ATCC10894, ATCC13073, 443 
and ATCC16424) was performed as singlicate according to M38-A methodology described by 444 
the Clinical and Laboratory Standards Institute (CLSI) (26) by Eurofins Panlabs Taiwan Ltd. 445 
(Taipei, Taiwan). 446 
 447 
In vitro antifungal activity against other fungal species. For the measurement of activity 448 
against C. gattii, the method described in EUCAST definitive document EDef 7.2 was used and 449 
assay plates were incubated statically at 37°C in ambient air for 24 h (± 2 h) unless poor growth 450 
necessitated further incubation to 36 or 48 h (42). Antifungal potency against Aspergillus flavus, 451 
Aspergillus niger and A. terreus, was determined as set out in EUCAST definitive document 452 
EDef 9.2 and assay plates were incubated at 37°C for 48 h (43). These tests were conducted at 453 
Evotec (UK) Ltd (Manchester, UK). Measurement of activity against other fungi was performed 454 
by Eurofins Scientific according to methodology described by the Clinical and Laboratory 455 
Standards Institute (CLSI) (CLSI M38-A (26) or M27-A2 (44), www.eurofinspanlabs.com). The 456 
source or strain name of each fungus species was indicated in Table 6. The MIC against C. 457 
 o
n
 M
arch 10, 2018 by University of W
ales Swansea
http://aac.asm
.org/
D
ow
nloaded from
 
AAC (Research Article, T.Colley/G.Sehra) 
22 
 
albicans, C.parapsilosis and C.glabrata were determined using an azole endpoint, which 458 
indicates 50% inhibition of fungus growth. 459 
 460 
In vitro fungicidal activity of PC1244 against A. fumigatus. The antifungal activity of PC1244 461 
against A. fumigatus [NCPF2010] was determined in 96-well plates using the methodology 462 
described above as duplicates, in three independent experiments. After the MIC for each 463 
compound was recorded, fungicidal activity was determined as previously described (35). 464 
Briefly, media from each well (100 μl/well) was removed after pipetting up and down five times 465 
and sub-cultured onto 4% Sabouraud dextrose agar plates. The plates were incubated (35°C with 466 
ambient air) for 48 h and the colony forming units (CFU) were counted for each compound 467 
concentration. The minimum fungicidal concentration (MFC) was determined as the lowest 468 
compound concentration yielding 3 colonies or less.  469 
 After removal of media for culture-based CFU testing, the contents of all wells were 470 
carefully aspirated and warm PBS (200 μl/well) was added. After gentle agitation, the contents of 471 
all wells were aspirated and fresh medium added (200 μl/well). The plates were incubated (35°C 472 
with ambient air) for 24 h. A working solution of 0.5 mg/ml XTT and 125 μM menadione was 473 
prepared in PBS and added across the plate (50 μl/well). The plates were incubated (35°C with 474 
ambient air) for 2 h, after which plates were agitated gently for 2 min. The optical density (OD) 475 
of each well at 450 nm and 620 nm was measured using a multi-scanner (Clariostar: BMG, 476 
Buckinghamshire, UK). The MFC (XTT-MFC) was calculated from the concentration-response 477 
curve generated using a cut-off of 99% inhibition. 478 
 479 
In vitro determination of persistence of action on A. fumigatus hyphae. The persistence of 480 
action of test agents was determined in A. fumigatus hyphae (NCPF2010) as previously reported 481 
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(28). Briefly, conidia diluted in growth media (RPMI-1640, 2 mM L-glutamine, 2% glucose, 482 
0.165 M MOPS, pH 7.0) were added across a 384-well plate at a final concentration of 483 
1x10
3
/well. After incubation at 35
o
C for exactly 6 h, test and reference articles or neat DMSO (as 484 
vehicle) (0.5 µl/well) were added to the appropriate wells to give a final concentration of 0.5% 485 
DMSO. The plates were incubated for exactly 20 minutes at 35
o
C and 5% CO2. After the 486 
incubation time had elapsed all wells on the designated washout plate were aspirated and growth 487 
media (100 µl/well) was added across the plate. For the non-washout plate, after compounds 488 
were added to hyphae, no media change was applied.  Resazurin (0.04% diluted in growth 489 
media) was added to all wells of both non-washout and washout plates (5 µl/well) to give a final 490 
concentration of 0.002% resazurin. The plates were incubated at 35
o
C and 5% CO2 for 16 h. 491 
Subsequently fluorescence in each well was measured at λex/λem 545/600 nm using a 492 
multiscanner (Clariostar: BMG, Buckinghamshire, UK). The percentage inhibition for each well 493 
was calculated and the IC50 value was calculated from the concentration-response curve 494 
generated for each test compound using a four-parameter logistic equation (Dotmatics, Bishops 495 
Stortford, UK). This study was conducted in quadricates, in three independent experiments. 496 
 497 
In vitro determination of persistence of action on bronchial epithelial cells. The persistence 498 
of action of test agents was evaluated in immortalised, bronchial, epithelial cells (BEAS2B) as 499 
previously reported (28). Each experiment consisted of one non-washout plate (96-well) and a 500 
parallel washout plate into which BEAS2Bs were seeded at a concentration of 3x10
4 
cells/well in 501 
growth media (RPMI-1640, 2 mM L-glutamine, 10% FCS), and incubated for 24 h at 37
o
C, 5% 502 
CO2. Test and reference articles or neat DMSO (as vehicle) (0.5 µl/well) were added to the 503 
appropriate wells of the washout plate to give a final concentration of 0.5% DMSO. The plate 504 
was incubated for exactly 1 h at 37
o
C and 5% CO2. After the incubation time had elapsed all 505 
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wells on the washout plate were aspirated and growth media (100 µl/well) was added across the 506 
plate. After 24 h incubation at 37°C, test and reference articles or neat DMSO (as vehicle) (0.5 507 
µl/well) were added to the appropriate wells of the non-washout plate to give a final 508 
concentration of 0.5% DMSO. The plate was incubated for exactly 1 h at 37
o
C and 5% CO2 after 509 
which A. fumigatus conidia were added across both plates at a final concentration of 1 x 10
3
/well. 510 
Fungal growth was determined after a further 24 h incubation at 35°C, 5% CO2, by measuring 511 
galactomannan (GM) concentrations, using Platelia GM-EIA kits (Bio-Rad Laboratories, 62794). 512 
The percentage inhibition for each well was calculated and the IC50 value was calculated from 513 
the concentration-response curve generated for each test compound using a four-parameter 514 
logistic equation (Dotmatics, Bishops Stortford, UK). This study was conducted in triplicates, in 515 
three independent experiments. 516 
 517 
In vivo antifungal activity against A. fumigatus infection. As previously reported (28), we 518 
tested antifungal effects of test articles on A. fumigatus infected, temporarily neutropenic mice.  519 
Specific pathogen-free A/J mice (male, 5 weeks old) were used for A. fumigatus infection as they 520 
have been described to be more susceptible to A. fumigatus infection previously (45). Animals 521 
(N=6 per group) were then dosed with hydrocortisone (Sigma H4881, 125 mg/kg, 522 
subcutaneously) on days 3, 2 and 1 before infection, and with cyclophosphamide (Sigma C0768; 523 
250 mg/kg, intraperitoneally) two days before infection to induce temporary neutropenia. Both 524 
hydrocortisone and cyclophosphamide were diluted with physiological saline. To avoid bacterial 525 
infection during immunosuppression, drinking water was supplemented with tetracycline 526 
hydrochloride (Sigma T7660; 1 μg/ml) and ciprofloxacin (Fluka 17850; 64 μg/ml). Conidia of A. 527 
fumigatus (ATCC13073 [strain: NIH 5233]) were aseptically dislodged from the malt agar plates 528 
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and suspended in sterile distilled water with 0.05% Tween 80 and 0.1% agar. On the day of 529 
infection, 30 μl (15 µl in each nostril) of the conidia suspension (1.67 × 108/ml in physiological 530 
saline) was administered intranasally under 3% isoflurane. 531 
Test agents, suspended in physiological saline, were administered intranasally (35 μl, 532 
approximately 17.5 µl each in each nostril), once daily, on days 1, 2 and 3 post infection. To 533 
investigate extended prophylaxis, PC1244 was administered intranasally once daily, on days -7 534 
to 0 and the effects were compared with treatment on days -1 to 0. As the injection volume was 535 
fixed and body weight was changed every day, especially after infection, the accurate dose unit 536 
was µg/mouse. However, as the average body weight after immunosuppression and just before 537 
infection was 20 g, we also calculated estimated dose as mg/kg. Therefore, 35 µl injections of 538 
0.0032, 0.016, 0.08, 0.4, 2 mg/ml were equivalent to 0.11, 0.56, 2.8, 14, 70 μg/mouse, 539 
respectively, which were approximately 0.0056, 0.028, 0.14, 0.7, 3.5 mg/kg, respectively (Table 540 
6). 541 
A body weight loss of > 20%, compared with an animal’s weight on day 1, or a mouse death, 542 
were both defined as “drop-out” events. Animals that lost > 20% of their initial body weight 543 
were sacrificed. Animals were terminally anaesthetised 6 h after the last dose of drug was 544 
administered on day 3. The volume inserted intranasally is reported to achieve almost 60% 545 
deposition into the lung (36).  546 
BALF was collected through cannulated tracheas using physiological saline (46), blood was 547 
then collected via cardiac puncture, and lung tissue was removed for homogenate preparation. 548 
The Aspergillus GM concentration in serum was determined with Platelia GM-EIA kits (Bio-Rad 549 
Laboratories, 62794). The value was provided as a “cut-off index” (COI) which was calculated 550 
by the formula: COI = OD in sample / OD in cut-off control, provided by the kit. For tissue 551 
fungal load, 100 mg of whole left lobe of lung tissue was removed aseptically and homogenized 552 
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in 0.2 ml of 0.1% agar in sterile distilled water as previously reported (28). We confirmed that 553 
the CFU level was not significantly different between the right lung and left lung. Serially 554 
diluted lung homogenates were plated on malt agar plates (50 μl/plate), and incubated at 24 ± 555 
1°C for 72 to 96 h. The colonies of A. fumigatus on each plate were counted and the fungal titre 556 
presented here as CFUs (x10
3
) per gram of lung tissue.  557 
Measurement of TNFα and IL-6 in serum and CXCL1 in BALF was performed using 558 
Quantikine
®
 mouse ELISA kit (R&D systems, Inc., Minneapolis, MN, USA). MDA 559 
(malondialdehyde) analysis was also performed using OxiSelect
®
 TBARS Assay Kit (MDA 560 
Quantitation; Cell Biolabs Inc, San Diego, CA, USA). For quantitative PCR, DNA amplification 561 
was performed with Premix Ex Taq
TM
 (Takara Bio, Kusatsu, Japan) and analysed in 96-well 562 
optical reaction plates, using the standard curve method. A. fumigatus 18S rRNA gene fragments 563 
were amplified with the primer pair; 5’-GGCCCTTAAATAGCCCGGT-3’ and 5’-564 
TGAGCCGATAGTCCCCCTAA-3’, and hybridization probe; 5’-FAM-565 
AGCCAGCGGCCCGCAAATG-TAMRA-3’. Each 25 µl reaction solution contained 50 ng of 566 
DNA from mice lungs and 200 nM of probe. The PCR protocol was as follows: incubation at 567 
50°C for 2 min and  95°C for 10 min; followed by 55 cycles of 65°C for 1 min and 95°C for 15 568 
sec. The fluorescence was monitored at the end of each cycle to obtain a measure of the amount 569 
of PCR product formed. The cycle numbers at which each sample reached the threshold were 570 
determined and the amounts of A. fumigatus DNA in 50 ng of mice lung DNA was evaluated 571 
from the standard curve with the cycle numbers and log2 concentrations of 0.05-50,000 pg of 572 
DNA from A. fumigatus. All animal studies were approved by the Ethics Review Committee for 573 
Animal Experimentation of Nihon University. A. fumigatus studies were approved by the 574 
Microbial Safety Management Committee of Nihon University School of Pharmacy (E-H25-575 
001). 576 
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 577 
Statistical analysis. Results are expressed as means ± standard error of the mean (SEM). For 578 
comparison between groups either the ordinary one-way ANOVA with Tukey’s post hoc 579 
comparison or the Kruskal-Wallis ANOVA with Dunn’s post hoc comparison test were 580 
performed. Statistical significance was defined as P<0.05. 581 
  582 
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FIGURE LEGENDS 739 
FIG 1 Structure of PC1244  740 
FIG 2  Inhibitory activity of PC1244 against 96 clinical isolates of A. fumigatus in France and 741 
UK. Each horizontal bar was presented as Geometric mean with 95% confidence interval.  742 
 743 
FIG 3 Efficacy of PC1244 on sterol 14α-demethylase (CYP51) activity. (A, B) Type II azole 744 
binding spectra for A. fumigatus CYP51A (A) and CYP51B (B), each experiment was performed 745 
4-6 times although only one replicate is shown, (C, D) Azole IC50 determinations of 746 
posaconazole () and PC1244 (), mean relative velocity values are shown with standard 747 
deviations for A. fumigatus CYP51A (C) and CYP51B (D).  748 
 749 
FIG 4 Duration of action of PC1244 against A. fumigatus. (A, B) Persistence of action of 750 
PC1244 (A) and voriconazole (B) on A. fumigatus hyphae, mean values and SEM of 3 751 
independent experiments (each experiment was conducted in quadricate), (C, D) Persistence of 752 
action of PC1244 (C) and voriconazole (D) on human bronchial cell lines (BEAS2B) infected 753 
with A. fumigatus, mean values and SEM of 3 independent experiments (each experiment was 754 
conducted in triplicate). 755 
 756 
FIG 5 Colorimetric microbroth assessment of fungicidal activity of PC1244 against A. fumigatus 757 
[NCPF2010] in vitro. Mean values and SEM of 3 independent experiments. 758 
 759 
FIG 6 Antifungal activity of PC1244 against A. fumigatus in vivo. PC1244 (0.0032, 0.0016 and 760 
0.08 mg/ml aqueous suspension) and posaconazole (0.08, 0.4 and 2 mg/ml aqueous suspension) 761 
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were intranasally given on days 1, 2 and 3 post infection of A. fumigatus in temporary 762 
neutropenic immunocompromised mice, Fungal load (CFU/g lung tissue) in lung (A), 763 
galactomannan (GM) in BALF (B) galactomannan (GM) in serum (C), CXCL1 in BALF (D), 764 
IL-6 in serum (E) and TNFα in serum (F) were evaluated on day 3 post infection (N=5~6). 765 
(N=6). Each horizontal bar was presented as mean ± SD from 5~6 mice per group. 
*
 P<0.05, 766 
**P<0.01, ***p<0.001 vs. infected control. “+” dead before sample collection. Serum could not 767 
collected from dead mice. 768 
 769 
FIG 7 Antifungal activity of extended prophylaxis treatment of PC1244 against A. fumigatus in 770 
vivo. Effects of 7 days extended prophylaxis with intranasal PC1244 was compared with that of 1 771 
day prophylaxis treatment only on lung fungal load (CFU/g tissue) (A), GM (COI) in serum (B) 772 
and malondialdehyde (MDA) in BALF (C) of A. fumigatus infected immunocompromised mice 773 
(N=4~5). Each horizontal bar was presented as mean ± SD from 4~6 mice per group. 
*
 P<0.05. 774 
 775 
FIG 8 Single prophylactic treatment of PC1244 and posaconazole against A. fumigatus in vivo.  776 
PC1244 at 0.4 mg/ml (14 µg/mouse) and posaconazole at 0.8 mg/ml (28 µg/mouse) were 777 
intranasally administered 16 h before A. fumigatus inoculation, and the lungs were collected for 778 
galactomannan (GM, COI) (A) and fungal load (CFU/g tissue) (B) assessment at 8 h after A. 779 
fumigatus inoculation. Each bar was presented as mean ± SD from 3~4 mice per group. 
*
 P<0.05. 780 
 781 
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TABLE 1 Antifungal effects of PC1244 and known antifungal agents in azole susceptible and azole resistant strains of A. fumigatus 
a
. 798 
 IC50 (IC90) (μg/ml) of indicated agent 
Strain PC1244  Voriconazole  Posaconazole  Itraconazole  Amphotericin B  Caspofungin 
NCPF2010 0.0017 (0.0022)  0.15 (0.21)  0.0070 (0.0084)  0.037 (0.054)  0.20 (0.62)  0.065 (>1) 
AF294 0.0021 (0.0041)  0.083 (0.27)  0.0056 (0.011)  0.041 (0.052)  0.21 (0.79)  >1 (>1) 
AF293 0.0026 (0.012)  0.25 (0.74)  0.010 (0.028)  0.032 (0.23)  0.24 (0.85)  >1 (>1) 
AF72 0.0024 (0.026)  0.025 (0.066)  0.042 (0.30)  0.31 (>1)  0.12 (0.42)  0.065 (>1) 
AF91 0.0037 (0.024)  0.14 (0.28)  0.038 (0.049)  0.22 (>1)  0.28 (0.75)  0.11 (>1) 
a
 IC50 and IC90 values were determined from optical density measurements. 799 
All compounds have been tested in a range of concentrations (0.002 ~ 1 µg/ml). The data are from 3 independent experiments and 800 
each test was performed in quadricate. 801 
 802 
 803 
 804 
 805 
 806 
 807 
 808 
 o
n
 M
arch 10, 2018 by University of W
ales Swansea
http://aac.asm
.org/
D
ow
nloaded from
 
AAC (Research article, Kimura et al) 
37 
 
TABLE 2 In vitro activities of PC1244, posaconazole and voriconazole against 96 clinically 809 
isolated A. fumigatus strains 
a
. 810 
 MIC (μg/ml)b 
Test Agent Range Geometric mean
 
Mode MIC50 MIC90 
PC1244 0.008 – 2 0.067**** 0.016 0.032 0.50 
Voriconazole 0.06 – 4 0.42 0.50 0.50 1.0 
Posaconazole 0.016 – 2 0.10**** 0.032 0.063 0.50 
a
All MIC were determined visually; MIC50 and MIC90 values represent the concentrations 811 
required to inhibit 50 and 90% of the strains tested. 812 
b****
, P < 0.0001; versus the results for voriconazole (One way ANOVA with Tukey’s test). 813 
 814 
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TABLE 3 Mean percentage sterol composition of A. fumigatus treated with either posaconazole 829 
(A) or PC1244 (B) of three biological replicates (± standard deviation from the mean). 830 
(A) 
Sterol 
Sterol compositions (posaconazole-treated [μg/ml]) 
DMSO 0.0001 0.001 0.01 0.1 1 
Ergosterol 100 (± 0) 94.5 (±0.1) 87.2 (±0.7) 74.7 (±0.8) 67.8 (±0.3) 67.4 (±1.5) 
Ergost-5,7-
dienol 
0  3.3 (±1.9) 3.9 (±0.6) 0 0 0 
Lanosterol 0 0 3.0 (±0.9) 7.0 (±0.3) 8.8 (±0.5) 8.8 (±0.4) 
Eburicol 0 2.2 (±1.2) 5.9 (±0.5) 18.3 (±1.1) 23.4 (±0.8) 23.8 (±1.3) 
 831 
(B) 
Sterol 
Sterol compositions (PC1244-treated [μg/ml]) 
DMSO 0.0001 0.001 0.01 0.1 1 
Ergosterol 100 (± 0) 91.3 (±0.1) 89.2 (±0.2) 76.8 (±2.6) 61.0 (±1.6) 58.7 (±2.2) 
Ergost-5,7-
dienol 
0 4.6 (±1.8) 4.6(±0.8) 0 0 0 
Lanosterol 0 1.7 (±0.7) 2.8 (±0.6) 8.5 (±1.1) 12.3 (±0.8) 13.1 (±0.9) 
Eburicol 0 2.5 (±1.1) 3.4 (±1.2) 14.7(±1.5) 26.7 (±0.8) 28.2 (±1.3) 
 832 
 833 
 834 
 835 
 836 
 837 
 838 
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TABLE 4 Potencies and persistence of action of PC1244, posaconazole and voriconazole in A. 845 
fumigatus hyphae and in BEAS2B cells infected with A. fumigatus. 846 
 Hyphae  BEAS2B 
 IC50 (μg/ml)
a 
  IC50 (μg/ml)  
Test Agent 
No 
washout Washout 
Fold 
change  
No 
washout Washout 
Fold 
change 
PC1244 0.00011
* 
0.00025 2.41  0.0034
* 
0.018 5.40 
Voriconazole 0.011 >1 >93  0.054 >1 >18.6 
Posaconazole 0.00045 0.0022 4.90  0.0031 0.046 14.7 
a*
, P < 0.05 for PC1244 versus the results for voriconazole (Kruskal-Wallis one-way ANOVA 847 
with Dunn’s test). 848 
Data are from 3 independent experiments, and each assay was conducted in quadricate for 849 
hyphae assay and in triplicate for BEAS2B assay. 850 
 851 
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TABLE 5 Mean fungicidal activity of PC1244, posaconazole and voriconazole against A. 863 
fumigatus (NCPF2010) of three biological replicates (± standard deviation from the mean).. 864 
 MIC/MFC (μg/ml)b [MFC/MIC ratio] 
Test Agent MIC CFU-MFC XTT-MFC 
PC1244 0.063 ± 0 2 [32] 0.14 [2.2] 
Voriconazole 1.67 ± 0.58 16 [9.6] >32 [>19] 
Posaconazole 0.125 ± 0 4 [32] 0.42 [3.4] 
Data are from 3 independent experiments, and each assay was conducted in duplicate.  865 
 866 
 867 
 868 
  869 
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TABLE 6 Conversion of units of dose give to mice in vivo study 870 
mg/ml aqueous suspension mg/mouse approx.mg/kg
1
 
0.0032 0.00011 0.0056 
0.016 0.00056 0.028 
0.08 0.0028 0.14 
0.4 0.014 0.70 
0.8 0.028 1.4 
2 0.07 3.5 
1. 20g is used for calculation as average body weight of used mice  871 
 872 
 873 
 874 
 875 
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TABLE 7 Antifungal effects of PC1244, voriconazole and posaconazole on other fungal species. 888 
Species (Strain[s])
 
Strains 
tested 
Culture 
method 
MIC (μg/ml) a 
PC1244 Voriconazole Posaconazole 
Aspergillus carbonarius 
(ATCC8740)
d
 
1 CLSI 0.063 0.5 0.063 
Aspergillus flavus  
(ATCC204304)
 d
 
1 CLSI 0.25 2 0.13 
Aspergillus flavus  
(AFL8; NRRC3357)  
2 EUCAST 0.38 0.63 0.16 
Aspergillus niger  
(ATCC1015)  
1 EUCAST 0.5 1 0.20 
Aspergillus terreus  
(AT49; AT7130)  
2 EUCAST 0.38 1 0.093 
Penicillium chrysogenum 
(ATCC9480)
 d
  
1 CLSI 0.13 2 0.13 
Penicillium citrinum 
(ATCC9849)
 d
  
1 CLSI 0.5 >8 0.5 
Trichophyton rubrum 
(ATCC10218)
 d
  
1 CLSI 0.031 0.063 0.031 
Aureobasidium pullulans 
(ATCC9348)
 d
 
1 CLSI 1 >8 1 
Cladosporium 
argillaceum 
(ATCC38013)
 d
 
1 CLSI 0.25 0.5 0.25 
Candida albicans 
(20240.047; ATCC 
10231)
 d
 
2 CLSI <0.0078
 b
 0.14
 b
 0.081
 b
 
Candida albicans-AR 
 c
 
(20183.073; 20186.025)
 d
 
2 CLSI 
(0.25, 
<0.0078)
 
b
 
10
 b
 8.13
 b
 
      
Candida glabrata  
(ATCC 36583; R363)
 d
 
2 CLSI 
(<0.0078, 
0.13)
 b
 
8.13
 b
 0.5
 b
 
      
Candida krusei  
(ATCC6258)
 d
 
1 CLSI 0.13 0.25 0.125 
Candida parapsilosis 
(ATCC22019)
 d
 
1 CLSI 0.25
 b
 NT 0.25
 b
 
Chaetomium globosum 
(ATCC44699)
 d
 
1 CLSI 0.063 1 0.25 
Gibberella zeae 
(Fusarium graminearum)  
(ATCC16106)
 d
 
1 CLSI 1 >8 >8 
Cryptococcus gattii 
(Clinical isolate) 
1 EUCAST 0.5 0.125 0.5 
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Cryptococcus neoformans 
(ATCC24067)
 d
 
1 CLSI 0.016 0.016 0.016 
Lichtheimia corymbifera 
(ATCC 7909) 
d
 
1 CLSI 1 >8 >8 
Mucor circinelloides 
(ATCC8542)
 d
 
1 CLSI 2 >8 >8 
Rhizomucor pusillus 
(ATCC16458)
 d
 
1 CLSI 2 >8 >8 
Rhizopus oryzae  
(ATCC11145)
 d
 
1 CLSI 0.25 >8 >8 
a
 Due to the limited number of strains tested, the mean of isolate MICs is presented. 889 
b
 MIC indicates 50% inhibition of fungal growth as azole readout. 890 
c
AR, azole resistant (fluconazole and voriconazole). 891 
d
 All details of isolate and assay protocol are described in https://www.eurofinspanlabs.com 892 
(Anti-infective assay/Fungi)  893 
NT = not tested. 894 
 895 
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